 Artist: Skyclad: mp3 download Genre(s): Metal Folk: Folk-Rock Metal: Heavy Metal: Thrash Rock Metal: Progressive Skyclad's discography:  A Semblance Of Normality Year: 2004 Tracks: 13  No Daylights Nor Heeltaps Year: 2002 Tracks: 10  Another Fine Mess Year: 2001 Tracks: 12  Folkemon Year: 2000 Tracks: 11  Vintage Whine Year: 1999 Tracks: 11  The Answer Machine? Year: 1997 Tracks: 13  Oui Avant-Garde A Chance Year: 1997 Tracks: 12  Irrational Anthems Year: 1996 Tracks: 13  The Silent Whales Of Lunar Sea Year: 1995 Tracks: 12  Prince Of The Poverty Line Year: 1994 Tracks: 11  Jona's ark Year: 1993 Tracks: 11  Tracks From The Wilderness Year: 1992 Tracks: 6  A Burnt Offering For The Bone Idol Year: 1992 Tracks: 11  The Wayward Sons Of Mother Earth Year: 1991 Tracks: 10 Based in Newcastle, England, the reformist thresh around metallic factor circle Skyclad was founded in 1990 by vocalizer Martin Walkyier, world Health Organization left field his previous circle, Sabbat, after an disputation with guitarist Andy Sneap. Walkyier added deuce old members of Pariah -- guitarist Steve Ramsey and bassist Graeme English -- as well as second guitarist Dave Pugh and drummer Keith Baxter. The band signed to the German Noise International mark and recorded Perverse Sons of Mother Earth for a 1991 release. After touring with Overkill and adding violinist/keyboardist Fritha Jenkins, Skyclad recorded A Burnt Offering for the Bone Idol in 1992 and Jonah's Ark the following year. Continuing their vent of an album each year through and through the mid-'90s, the mathematical group issued Prince of the Poverty Line in 1994, with Cath Howell replacement Jenkins. Howell was in call on replaced by Georgina Biddle for 1995's The Silent Whales of Lunar Sea, later on which Baxter and Pugh left the group. Irrational Anthems and Oui Avant-Garde a Chance followed in 1996, both with studio apartment drummers, and both afterwards on reissued by Century Media; The Answer Machine continued the band's prolific recording schedule in 1997. Permanent replacements for Pugh and Baxter at retentive last sign-language on in 1998 in the mortal of drummer Jay Graham and guitarist Keith Ridley, world Health Organization debuted on 1999's Vintage Whine. The punningly highborn Folkemon appeared in Europe in 2000 and the U.S. in early 2001, marking the band's first offer for Nuclear Blast. |
Sunday, 7 September 2008
Mp3 music: Skyclad
Thursday, 28 August 2008
New Prostate Cancer Test Is Ready For Commercialization Following Successful Completion Of Final Clinical Trials
�Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced that HDC's new gene-based molecular diagnostic test for prostate cancer has now successfully completed it's Phase III double-blind clinical trial and is forthwith ready for commercialization to be used by physicians on their patients at risk of having prostate cancer. The new prostate cancer quiz will be performed at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royal family on each test performed.
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very heights success pace for identifying the presence of Grade 3 or higher prostate gland cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently realised double-blinded clinical validation studies demonstrated that the young gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for right identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall try accuracy of 93%.
"We are selfsame pleased with the net results of the double blind clinical trial and are excited to have our first tax income producing molecular diagnostic test ready for commercialization," declared Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "The successful ontogeny, validation and commercialization of this new molecular symptomatic test for prostate malignant neoplastic disease proves that HDC, by combining our patented SVM and SVM-RFE technology and our expert Scientific Team, has the ability to produce new molecular symptomatic and portent tests which are the future of personalized medicine. Our patent protected discovery method allows us to develop molecular diagnostic and prognostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our molecular diagnostic factor signatures. Using the same expertise of our Scientific Team and the HDC patented engineering, we are currently development additional unexampled molecular symptomatic tests in a variety of other cancers some of which we hope will be commercially uncommitted in Q4 of 2008."
Dr. Barnhill continued "We are proud of to take in HDC's new gene-based prostate cancer quiz enter the market like similar molecular diagnostic tests based on unique cistron expression profiles such as OncotypeDX from Genomic Health, Inc. (NasdaqGM:GHDX) and MammaPrint from Agendia."
In the United States alone thither are over 1 1000000 prostate genus Cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies ar reported "cocksure" indicating the presence of prostate crab. The other 75% of prostate cancer tissue biopsies are reported as "negative" for the presence of cancer. However, one-third of the workforce with initial prostate cancer tissue biopsies that are reported as "negative" for prostate crab (roughly 25% of men at risk of having prostate crab) actually do have prostate cancer that was lost by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation's prostate cancer molecular diagnostic test is a genomics based test that should be performed on the 75% of men (about 600,000 men each year in the US unequaled) with initial biopsies reported as negative to attend physicians in identifying those men world Health Organization could get prostate cancer that was missed by the low biopsy.
"The excellent results seen in Phase I, Phase II, and Phase III double-blinded clinical trials validate the scientific truth and robustness of the HDC gene-based molecular symptomatic test for prostate cancer," stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. "Physicians that ar diagnosing and treating prostate gland cancer patients will be greatly assisted by the additional information that this new prostate cancer quiz will add together to their decision devising process."
In a Press Release issued yesterday, Ron Andrews, CEO of Clarient stated "We are selfsame impressed with the results from these validation studies, and I applaud the development teams from both Clarient and HDC for their persevering efforts in bringing this new test through the validation phase angle significantly ahead of schedule. The early results from these studies confirm our belief that this potent genomics-based test may leave physicians with useful information to assure that men with prostate cancer catch a more accurate diagnosis sooner and minimize the need for unnecessary biopsies."
HDC plans to straight off begin presenting papers for publication and presentations at upcoming meetings as we initiate the marketing phase of commercialization. Because of the clinical trial success of this prostate malignant neoplastic disease test, the company plans to lead up a subject area utilizing piss samples to potentially enlarge the indication of this new prostate gland cancer test to be used as a screening tool, which could significantly expand the current market opportunity to include all men at risk for prostate cancer.
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the force field of rule recognition engineering. Through the application of its patent protected engineering science, HDC is a leader in SVM-based molecular symptomatic and prodigy test evolution in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM radiation pattern recognition tools have significant application potential difference in other sizable commercial markets such as oil exploration, fiscal markets, Internet search and spam, native land security, and other areas where analysis of large volumes of complex information is requisite.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can fall in no assurance that such expectations will prove correct.
Health Discovery Corporation
More info
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very heights success pace for identifying the presence of Grade 3 or higher prostate gland cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently realised double-blinded clinical validation studies demonstrated that the young gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for right identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall try accuracy of 93%.
"We are selfsame pleased with the net results of the double blind clinical trial and are excited to have our first tax income producing molecular diagnostic test ready for commercialization," declared Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "The successful ontogeny, validation and commercialization of this new molecular symptomatic test for prostate malignant neoplastic disease proves that HDC, by combining our patented SVM and SVM-RFE technology and our expert Scientific Team, has the ability to produce new molecular symptomatic and portent tests which are the future of personalized medicine. Our patent protected discovery method allows us to develop molecular diagnostic and prognostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our molecular diagnostic factor signatures. Using the same expertise of our Scientific Team and the HDC patented engineering, we are currently development additional unexampled molecular symptomatic tests in a variety of other cancers some of which we hope will be commercially uncommitted in Q4 of 2008."
Dr. Barnhill continued "We are proud of to take in HDC's new gene-based prostate cancer quiz enter the market like similar molecular diagnostic tests based on unique cistron expression profiles such as OncotypeDX from Genomic Health, Inc. (NasdaqGM:GHDX) and MammaPrint from Agendia."
In the United States alone thither are over 1 1000000 prostate genus Cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies ar reported "cocksure" indicating the presence of prostate crab. The other 75% of prostate cancer tissue biopsies are reported as "negative" for the presence of cancer. However, one-third of the workforce with initial prostate cancer tissue biopsies that are reported as "negative" for prostate crab (roughly 25% of men at risk of having prostate crab) actually do have prostate cancer that was lost by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation's prostate cancer molecular diagnostic test is a genomics based test that should be performed on the 75% of men (about 600,000 men each year in the US unequaled) with initial biopsies reported as negative to attend physicians in identifying those men world Health Organization could get prostate cancer that was missed by the low biopsy.
"The excellent results seen in Phase I, Phase II, and Phase III double-blinded clinical trials validate the scientific truth and robustness of the HDC gene-based molecular symptomatic test for prostate cancer," stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. "Physicians that ar diagnosing and treating prostate gland cancer patients will be greatly assisted by the additional information that this new prostate cancer quiz will add together to their decision devising process."
In a Press Release issued yesterday, Ron Andrews, CEO of Clarient stated "We are selfsame impressed with the results from these validation studies, and I applaud the development teams from both Clarient and HDC for their persevering efforts in bringing this new test through the validation phase angle significantly ahead of schedule. The early results from these studies confirm our belief that this potent genomics-based test may leave physicians with useful information to assure that men with prostate cancer catch a more accurate diagnosis sooner and minimize the need for unnecessary biopsies."
HDC plans to straight off begin presenting papers for publication and presentations at upcoming meetings as we initiate the marketing phase of commercialization. Because of the clinical trial success of this prostate malignant neoplastic disease test, the company plans to lead up a subject area utilizing piss samples to potentially enlarge the indication of this new prostate gland cancer test to be used as a screening tool, which could significantly expand the current market opportunity to include all men at risk for prostate cancer.
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the force field of rule recognition engineering. Through the application of its patent protected engineering science, HDC is a leader in SVM-based molecular symptomatic and prodigy test evolution in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM radiation pattern recognition tools have significant application potential difference in other sizable commercial markets such as oil exploration, fiscal markets, Internet search and spam, native land security, and other areas where analysis of large volumes of complex information is requisite.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can fall in no assurance that such expectations will prove correct.
Health Discovery Corporation
More info
Monday, 18 August 2008
Mp3 music: Wicked Lester
 Artist: Wicked Lester: mp3 download Genre(s): Other Wicked Lester's discography:  The Original Wicked Lester Session Year: 1972 Tracks: 9 Although the band Wicked Lester never issued an official recording during their brief tenure together, the grouping would serve as a stepping stone for both Gene Simmons and Paul Stanley, both of whom later went on to discrepancy 1 of the '70s biggest punishing rock outfits, Kiss. Simmons and Stanley met in the late '60s through a mutual friend, Steve Coronel, barely it wasn't until Wicked Lester was formed in the early '70s that they reached whatever arcdegree of success. In add-on to Simmons (bass and vocals) and Stanley (guitar and vocals), the group likewise in the first place featured Coronel (cut guitar), Tony Zarella (drums), and Brooke Ostrander (keyboards), as the quint received a transcription contract from Columbia afterwards only playing a handful of gigs in the New York area. Only the take came with one stipulation, that Coronel be replaced with a more complete participant. The request was granted (regular though Simmons and Coronel had been longtime friends), as some other guitar player, Ron Leejack, signed on. The newly instated lineup recorded an album's charles Frederick Worth of tracks at Jimi Hendrix's illustrious Electric Lady Studios in 1971, just the songs were the nail opposite of the orbit anthem/heavy metallic element that Kiss would after specialise in -- Wicked Lester was more a family to the chart-topping soft john Rock of the day (Rod Stewart, etc.), as their sound was an dental amalgam of several styles, something that Simmons and Stanley didn't feel very comfy with. Not glad with how the record album came out or the band's musical focus, the founding duet promptly announced their divergence from Wicked Lester, and the accomplished record album was shelved. When Simmons and Stanley hit the magnanimous time with Kiss in the mid to late '70s, the unreleased Wicked Lester album gained major interest group among Kiss fans -- particularly later on a pair off of Wicked Lester songs, "She" and "Love Her All I Can," were re-cut by Kiss themselves for their 1975 Dressed to Kill album (some other early Kiss song, "Goin' Blind," was credited to both Simmons and Coronel, just appears to have been written either earlier or after Wicked Lester). The unreleased Wicked Lester album (and its art) was bought by Kiss' label, Casablanca, in 1977 so that Columbia wouldn't hard cash in on Kiss' success by releasing the aborted track record (which besides included pictures of Simmons and Stanley without make-up), only bootleg copies of the record album finally began making the rounds in fan circles. 2001 saw the appearance of the number 1 officially released Wicked Lester tracks ("Observe Me Waiting," as well as the said "She" and "Sexual love Her All I Can") on Kiss' self-titled, five-disc box mark. |
Friday, 8 August 2008
Joss Stone playing homely wife in "Tudors"
LOS ANGELES (Hollywood Reporter) - In her first major acting use, British soul singer Joss Stone will play Henry VIII's one-quarter wife, Anne of Cleves, in Showtime's drama "The Tudors."
The gig will likely be a brief one, as Anne was married to Henry (Jonathan Rhys Meyers) for around six months.
A daughter of a German nobleman, Anne was betrothed to Henry in a marriage accord between the Cleves Court and the king's chancellor after Henry was shown a portrait of her.
Upon Anne's comer in England, Henry was disappointed in her looks and before long found a legal way to have the married couple annulled.
According to Showtime, the upcoming time of year of the racy imperial drama will follow the king as he weds Jane Seymour (Anita Briem) and then Anne of Cleves.
Stone, who explode onto the music picture in 2003 and has had threesome gold albums in the U.S., has been looking to bilk over into acting. In 2006, she had a role in the fantasy feature "Eragon." She is working on a new album.
/Hollywood Reporter
More information
Tuesday, 1 July 2008
Complete list of winners at the 35th annual Daytime Emmys
Complete list of winners at the 35th annual Daytime Emmys:
-Outstanding Supporting Actress in a Drama Series: Gina Tognoni, CBS' "Guiding Light."
-Outstanding Talk Show - Informative: "The Tyra Banks Show."
-Outstanding Younger Actor in a Drama Series: Tom Pelphrey, CBS' "Guiding Light."
-Outstanding Younger Actress in a Drama Series: Jennifer Landon, CBS' "As the World Turns"
-Outstanding Talk Show Host: Ellen DeGeneres, "The Ellen DeGeneres Show."
-Outstanding Drama Series Directing Team: "One Life to Live."
-Outstanding Legal/Courtroom Program: "Cristina's Court."
-Outstanding Supporting Actor in a Drama Series: Kristoff St. John, CBS' "The Young and the Restless."
-Outstanding Drama Series Writing Team: "One Life to Live."
-Outstanding Talk Show - Entertainment: "Rachael Ray."
-Lifetime Achievement Award: Regis Philbin.
-Outstanding Lead Actress in a Drama Series: Jeanne Cooper, CBS' "The Young and the Restless."
-Outstanding Lead Actor in a Drama Series: Anthony Geary, ABC's "General Hospital."
-Outstanding Drama Series: ABC's "General Hospital."
See Also
Thursday, 19 June 2008
Your V-Fest checklist
You don't want little things to interfere with your V-Fest experience, whether it be because you forgot extra socks or you get your samurai sword confiscated at the gate. Here's a list to help you pack your things and to save you the trauma of losing your belongings.
What to Remember
- Photo ID
- Cash (but not, like, thousands of dollars)
- An emergency stash of toilet paper and hand sanitizer
- Camera (just a compact digital, point and shoot or disposable one)
- Batteries or film for said camera
- Sunscreen
- One sealed bottle of water
- Extra socks
- A Sharpie and autograph book just in case
- Earplugs (Your parents are right � you WILL damage your hearing!)
- Headache medicine
- Deodorant please.
- A compact poncho in case it rains
- Some small snacks
- Something to keep you warm at night
- Bug spray
- A hat
- Um . . .your ticket.
What to Forget
- Fancy SLR or DSLR cameras or any form of audio and/or video recording equipment
- Umbrella
- Big backpacks or large bags
- Skateboards, rollerblades, bicycles, unicycles, scooters, hoverboards, etc
- Your pet or other random animal
- Things that can hurt people, like knives, guns, batons, shards of glass, explosive devices (including fireworks)
- Recreational drugs and/or alcohol
- Any form of glass bottle or container
- Laser pointers
- Generators
- Lawnchairs or other furniture
- Loud horns or noise makers
- Tents
- Big, clunky coolers
- Frisbees or other things that can be thrown and hit someone in the back of the head, causing pain
- Priceless items that can be lost or damaged
See Also
Wednesday, 11 June 2008
A new harmony for music labels, TV
It's the sobering reality of today's music business -- a record company executive can sign a new act and then tell her, "Keep your day job."
That was one message neo-soul singer Sharon Little got from Larry Jenkins, head of the new CBS Records label, an offshoot not of Sony-owned Columbia Records but an arm of CBS Television.
It's equally telling that since hearing that advice when she signed last fall, Little's response has been gratitude, not animosity.
"It wasn't like they said, 'Here's $50,000 so we can sign you'; it was, 'We'll give you a small advance, but here's all the stuff we're going to do for you,' " said Little, a 27-year-old singer and songwriter who did indeed hold onto her job as a waitress in Philadelphia while recording her debut album this year.
"It was like tough love in a way," she added. "You have to work harder to get where you want to be because you don't have all this money up front to fall back on."
That's one way this new label with an old name is trying to blaze a different path in the ailing record business.
Nancy Tellem, who heads CBS' network and television studio's entertainment division, spearheaded the launch of the label in 2006. The underlying business strategy is twofold: Save on music licensing by building a small stable of acts whose recordings would be owned by the parent group and generate revenue for CBS if any of those acts get a hit.
But for Jenkins, a veteran music publicist who left the Sony family of labels five years ago, it represented a new opportunity to revisit some old values.
"I spent an entire career at the major labels," Jenkins said, "and I learned a lot of what to do -- and a lot of what to avoid. I thought, 'What if we went into this where we'll only sign artists who are really talented? The kind of artists you can bring to your office with acoustic guitar or a keyboard and they sing and play great. The real deal."
For him, that's a group of acts that are all essentially singer-songwriters, including Little, who will open for Robert Plant and Alison Krauss on tour this summer, Keaton Simons, Karmina (sisters Kelly and Kamille Rudisill), Will Dailey, and PJ Olsson.
During the last year while CBS Records has been gearing up -- a period in which the original business plan was interrupted by the writers strike -- the label's acts have landed music on TV about 80 times, Jenkins said.
That's a small slice of what he says is more than 2,000 music placements in CBS prime-time shows alone in a given season. It constitutes, he said, "a small dent." But it's a meaningful one to aspiring musicians.
"There's a huge television audience out there, particularly with shows like 'CSI' and 'Grey's Anatomy,' " said Kelly Rudisill. "That's really good for artists like us."
It also provides TV's creative types with what essentially is a one-stop shop for music.
"Two months ago, the label had a showcase with Will Dailey, Sharon Little and Keaton Simons, and within a month of that show, we had used a song from each in our series," said Joshua Rexon, producer of "NCIS." "It's a great relationship."
That relationship cuts two ways. Most of the time, the CBS acts get a five- or 10-second promo at the end of any show their music appears in, directing viewers to the artists' websites or retailers such as iTunes or Amazon.
Other networks have made similar moves. For the last several years, NBC Universal and Target stores have collaborated on a series of holiday music releases. ABC and Disney tag team with Hollywood Records releases from musicians featured on the ABC-owned Disney Channel.
Of course, the potential dark side of a TV network with an in-house music library that's essentially free -- and also eventually could generate additional revenue for the corporate parent -- is that bigwigs might insist that underlings use it.
"Nobody has ever told me to take a song out and put a CBS song in," said Ken Sanzel, executive producer of the crime drama "Numb3rs," which has tapped songs from Simons and Little in recent episodes. "And when I look at our shows, we still have a lot more non-CBS than CBS music."
Said Jenkins: "If a show wants Coldplay or AC/DC, they're not going to take our brand-new artists instead. It's not like this label is intended to replace the rest of music industry."
By the same token, Jenkins' vision isn't restricted to CBS, and he noted that one of Dailey's songs made the cut for a show on ABC.
The new model won't work all the time, even at CBS. Veteran music supervisor Gary Calamar ("Six Feet Under, "Weeds," "Dexter") recently has been scouting songs to use in CBS' series "Swingtown."
"I did have a meeting with the CBS Records people and talked about using some of their music," he said. "Unfortunately, because it's a period piece, set in 1976, and the producers really want to stick with recordings from that period, we couldn't use any of them. . . . In this particular case it didn't make sense. But when it does, that kind of resource would be great to have."
The label is just now putting out its first physical CDs for conventional and online retailers. Little's album came out May 27, Karmina's hit Tuesday and Simons' debut is due next week.
Jenkins likes to talk about another aspect of CBS that's something of a throwback: community. Simons is touring this summer with Dailey, and Karmina's Kelly has joined Simons on stage.
"It's a small family but a very close family. It really is," Karmina's Kamille said. "Everyone works really hard together. We all get along and go to each other's shows."
Said Sharon Little: "It's kind of neat to be signed to a label that's a major label but that has an indie feel. It's like that really popular kid at school who also turns out to be really nice."
randy.lewis@latimes.com
That was one message neo-soul singer Sharon Little got from Larry Jenkins, head of the new CBS Records label, an offshoot not of Sony-owned Columbia Records but an arm of CBS Television.
It's equally telling that since hearing that advice when she signed last fall, Little's response has been gratitude, not animosity.
"It wasn't like they said, 'Here's $50,000 so we can sign you'; it was, 'We'll give you a small advance, but here's all the stuff we're going to do for you,' " said Little, a 27-year-old singer and songwriter who did indeed hold onto her job as a waitress in Philadelphia while recording her debut album this year.
"It was like tough love in a way," she added. "You have to work harder to get where you want to be because you don't have all this money up front to fall back on."
That's one way this new label with an old name is trying to blaze a different path in the ailing record business.
Nancy Tellem, who heads CBS' network and television studio's entertainment division, spearheaded the launch of the label in 2006. The underlying business strategy is twofold: Save on music licensing by building a small stable of acts whose recordings would be owned by the parent group and generate revenue for CBS if any of those acts get a hit.
But for Jenkins, a veteran music publicist who left the Sony family of labels five years ago, it represented a new opportunity to revisit some old values.
"I spent an entire career at the major labels," Jenkins said, "and I learned a lot of what to do -- and a lot of what to avoid. I thought, 'What if we went into this where we'll only sign artists who are really talented? The kind of artists you can bring to your office with acoustic guitar or a keyboard and they sing and play great. The real deal."
For him, that's a group of acts that are all essentially singer-songwriters, including Little, who will open for Robert Plant and Alison Krauss on tour this summer, Keaton Simons, Karmina (sisters Kelly and Kamille Rudisill), Will Dailey, and PJ Olsson.
During the last year while CBS Records has been gearing up -- a period in which the original business plan was interrupted by the writers strike -- the label's acts have landed music on TV about 80 times, Jenkins said.
That's a small slice of what he says is more than 2,000 music placements in CBS prime-time shows alone in a given season. It constitutes, he said, "a small dent." But it's a meaningful one to aspiring musicians.
"There's a huge television audience out there, particularly with shows like 'CSI' and 'Grey's Anatomy,' " said Kelly Rudisill. "That's really good for artists like us."
It also provides TV's creative types with what essentially is a one-stop shop for music.
"Two months ago, the label had a showcase with Will Dailey, Sharon Little and Keaton Simons, and within a month of that show, we had used a song from each in our series," said Joshua Rexon, producer of "NCIS." "It's a great relationship."
That relationship cuts two ways. Most of the time, the CBS acts get a five- or 10-second promo at the end of any show their music appears in, directing viewers to the artists' websites or retailers such as iTunes or Amazon.
Other networks have made similar moves. For the last several years, NBC Universal and Target stores have collaborated on a series of holiday music releases. ABC and Disney tag team with Hollywood Records releases from musicians featured on the ABC-owned Disney Channel.
Of course, the potential dark side of a TV network with an in-house music library that's essentially free -- and also eventually could generate additional revenue for the corporate parent -- is that bigwigs might insist that underlings use it.
"Nobody has ever told me to take a song out and put a CBS song in," said Ken Sanzel, executive producer of the crime drama "Numb3rs," which has tapped songs from Simons and Little in recent episodes. "And when I look at our shows, we still have a lot more non-CBS than CBS music."
Said Jenkins: "If a show wants Coldplay or AC/DC, they're not going to take our brand-new artists instead. It's not like this label is intended to replace the rest of music industry."
By the same token, Jenkins' vision isn't restricted to CBS, and he noted that one of Dailey's songs made the cut for a show on ABC.
The new model won't work all the time, even at CBS. Veteran music supervisor Gary Calamar ("Six Feet Under, "Weeds," "Dexter") recently has been scouting songs to use in CBS' series "Swingtown."
"I did have a meeting with the CBS Records people and talked about using some of their music," he said. "Unfortunately, because it's a period piece, set in 1976, and the producers really want to stick with recordings from that period, we couldn't use any of them. . . . In this particular case it didn't make sense. But when it does, that kind of resource would be great to have."
The label is just now putting out its first physical CDs for conventional and online retailers. Little's album came out May 27, Karmina's hit Tuesday and Simons' debut is due next week.
Jenkins likes to talk about another aspect of CBS that's something of a throwback: community. Simons is touring this summer with Dailey, and Karmina's Kelly has joined Simons on stage.
"It's a small family but a very close family. It really is," Karmina's Kamille said. "Everyone works really hard together. We all get along and go to each other's shows."
Said Sharon Little: "It's kind of neat to be signed to a label that's a major label but that has an indie feel. It's like that really popular kid at school who also turns out to be really nice."
randy.lewis@latimes.com
Subscribe to:
Posts (Atom)